2022
Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease
Ben Bashat D, Thaler A, Lerman Shacham H, Even-Sapir E, Hutchison M, Evans K, Orr-Urterger A, Cedarbaum J, Droby A, Giladi N, Mirelman A, Artzi M. Neuromelanin and T2*-MRI for the assessment of genetically at-risk, prodromal, and symptomatic Parkinson’s disease. Npj Parkinson's Disease 2022, 8: 139. PMID: 36271084, PMCID: PMC9586960, DOI: 10.1038/s41531-022-00405-9.Peer-Reviewed Original ResearchParkinson's diseaseGenotype-related differencesDAT-SPECTRadiomic featuresSymptomatic Parkinson's diseaseSignificant correlationProdromal phaseBrain regionsNeuromelanin MRIIron accumulationDiseaseMRIAssessment of individualsImaging valuesRadiomics analysisSignificant differencesPatientsNeuromelaninRiskAgeScoresT2Ratio scoresGroupLR scores
2012
BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA
CESARI M, FIELDING R, PAHOR M, GOODPASTER B, HELLERSTEIN M, ABELLAN VAN KAN G, ANKER S, RUTKOVE S, VRIJBLOED J, ISAAC M, ROLLAND Y, M’RINI C, AUBERTIN-LEHEUDRE M, CEDARBAUM J, ZAMBONI M, SIEBER C, LAURENT D, EVANS W, ROUBENOFF R, MORLEY J, VELLAS B. BIOMARKERS OF SARCOPENIA IN CLINICAL TRIALS RECOMMENDATIONS FROM THE INTERNATIONAL WORKING GROUP ON SARCOPENIA. The Journal Of Frailty & Aging 2012, 1-9. DOI: 10.14283/jfa.2012.17.Peer-Reviewed Original ResearchSkeletal muscle declineInternational Working GroupMuscle declineAge-related skeletal muscle declineBiomarkers of sarcopeniaClinical trial recommendationsSkeletal musclePublic health priorityAvailable biomarkersPotential great benefitAge-related modificationsClinical trialsTrial recommendationsHealth prioritySarcopeniaTherapeutic strategiesOlder personsWorking GroupOlder peopleBiomarkersMuscleSpecific recommendationsNegative outcomesGreat benefitGroup